GlassScriptPhysician profile
Garred R Cline
NPI 1295146710
$2,371.81
in general payments reported to CMS, 2019-2025
21 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $172 · 2021: $319 · 2022: $357 · 2023: $376 · 2024: $587 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $417.62 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.31 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $322.59 | 2019-2022 | |
| Shionogi INC | $249.98 | 2024-2025 | Fetroja |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.50 | 2019-2025 | Lifevest |
| Abbott Laboratories | $154.22 | 2024 | Cardiomems |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.60 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $98.38 | 2019-2025 | Brilinta |
| Philips North America LLC | $86.19 | 2023 | |
| La Jolla Pharmaceutical Company | $75.33 | 2022-2023 | Xerava |
| Allergan, INC. | $58.04 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $56.87 | 2023-2025 | Terlivaz |
| Daiichi Sankyo INC. | $43.77 | 2019-2021 | |
| Abbvie INC. | $43.26 | 2023-2025 | Avycaz |
| Gilead Sciences, INC. | $30.84 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $24.64 | 2023 | |
| Csl Behring | $21.54 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2020 | |
| Genentech USA, INC. | $13.86 | 2019 | |
| Smith+Nephew, INC. | $13.47 | 2025 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garred Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.